Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endolysin gel is a topical therapeutic formulation containing bacteriophage-derived endolysin enzymes, specifically developed for the treatment of mild to moderate atopic dermatitis. Endolysins are highly specific hydrolases that target and degrade the peptidoglycan layer of the bacterial cell wall, leading to rapid osmotic lysis of the pathogen. In the context of atopic dermatitis, this gel is designed to selectively eliminate *Staphylococcus aureus*, a bacterium that frequently colonizes the skin of patients and exacerbates inflammatory symptoms, while preserving the beneficial commensal skin flora. The drug is currently being evaluated in clinical trials, such as those sponsored by Shenzhen Qianhai Shekou Free Trade Zone Hospital, to assess its safety and efficacy in reducing disease severity and improving skin barrier function in adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on endolysin gel.